NASD · Healthcare · Biotechnology · USA
Denali Therapeutics Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.
Denali Therapeutics is a biopharmaceutical company discovering and developing medicines for serious diseases by using its proprietary TransportVehicle technology to deliver large molecule therapeutics across the blood-brain barrier. The company has programs in rare lysosomal storage disorders and common neurodegenerative diseases including Alzheimer's and Parkinson's disease, with a clinical-stage portfolio spanning enzyme, oligonucleotide, and antibody therapeutics.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Denali Therapeutics Inc stock.
Overvalued: intrinsic value $3.32 per share, market price $18.00, margin of safety -442.6% (as of 2026-11-17).
A 2.4x revenue multiple, discounted for its losses, values the shares at $3.32; the price of $18.00 is 443% above that value.
17 more funds hold it; the full list is part of the paid plan.
89 more in this industry show a wider margin of safety.
DNLI is overvalued (as of the 2026-11-17 close). A 2.4x revenue multiple, discounted for its losses, values the shares at $3.32; the price of $18.00 is 443% above that value.
$3.32 per share (as of the 2026-11-17 close), against a market price of $18.00. That is a margin of safety of -442.6%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.